Cantor Fitzgerald Reiterates Overweight on Pfizer, Maintains $45 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Pfizer (NYSE:PFE) and maintains a $45 price target.
June 26, 2024 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Louise Chen has reiterated an Overweight rating on Pfizer and maintained a $45 price target, indicating confidence in the company's future performance.
The reiteration of an Overweight rating and a maintained price target of $45 by a reputable analyst suggests positive sentiment and confidence in Pfizer's future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100